A novel use of TAT-EGFP to validate techniques to alter osteosarcoma cell surface glycosaminoglycan expression

Kumarasuriyar, A, Dombrowski, C, Rider, DA, Nurcombe, V and Cool, SM (2007) A novel use of TAT-EGFP to validate techniques to alter osteosarcoma cell surface glycosaminoglycan expression. Journal of Molecular Histology, 38 5: 435-447.


Author Kumarasuriyar, A
Dombrowski, C
Rider, DA
Nurcombe, V
Cool, SM
Title A novel use of TAT-EGFP to validate techniques to alter osteosarcoma cell surface glycosaminoglycan expression
Journal name Journal of Molecular Histology   Check publisher's open access policy
ISSN 1567-2379
Publication date 2007
Sub-type Article (original research)
DOI 10.1007/s10735-007-9136-z
Volume 38
Issue 5
Start page 435
End page 447
Total pages 13
Editor Key, B
Place of publication Dordrecht
Publisher Springer
Collection year 2008
Language eng
Subject C1
320602 Cell Physiology
780105 Biological sciences
Abstract Several methods to alter cell surface glycosaminoglycan (GAG) expression have previously been described, including treatments with chlorate to reduce the addition of charged sulfate groups, xyloside compounds to displace GAGs from their core proteins, and GAG lyases, such as heparinase and chondroitinase, to release GAG fragments from the cell layer. While these methods are useful in identifying cellular mechanisms which are dependent on GAGs, they must be stringently validated to assess results in the appropriate context. To determine the most useful technique for the evaluation of GAG function in osteogenesis, MG-63 osteosarcoma cells were systematically treated with these agents and evaluated for changes in cell surface GAGs using a TAT-EGFP fusion protein. TAT, a protein transduction domain from the HIV-1 virus, requires cell surface GAGs to traverse cell membranes. The EGFP component provides a method to assess protein entry into cells in both qualitative and quantitative tests. Here, TAT-EGFP transduction analysis confirmed radiochemical and physiological data that chlorate effectively disrupts GAG expression. TAT-EGFP entry into cells was also inhibited by the exogenous application of commercial heparin and GAGs extracted from MG-63 cells as well as by the pre-treatment of cells with chondroitinase ABC. However, neither heparinase III treatment nor the addition of exogenous chondroitin-6-sulfate affected TAT-EGFP entry into cells. In addition, xyloside-beta-D-naphthol and xyloside-beta-D-cis/trans-decahydro-2-naphthol treatment could not induce significant phenotypic change in these cells, and the unaffected TAT-EGFP transduction confirmed that this was due to an inability to efficiently prime GAG synthesis. The use of TAT-EGFP is thus a useful technique to specifically evaluate cell surface GAG expression in a simple, quantifiable manner, and avoids the complications involved with conventional radiochemical assays or analytical chromatography.
Keyword Cell Biology
TAT
EGFP
bone
osteosarcoma
osteoblast
MG-63
glycosaminoglycan
GAG
chlorate
xyloside
heparinase
chondroitinase
Heparan-sulfate Proteoglycans
Human-immunodeficiency-virus
Fibroblast-growth-factor
Beta-d-xylosides
Protein Transduction Domain
Trans-activator Protein
Hiv-1 Tat
Alkaline-phosphatase
Flavobacterium-heparinum
Chondroitin Sulfate
Q-Index Code C1
Q-Index Status Confirmed Code

 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 4 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 5 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Access Statistics: 85 Abstract Views  -  Detailed Statistics
Created: Mon, 18 Feb 2008, 15:33:16 EST